Parker Institute for Cancer Immunotherapy shared on LinkedIn:
“Congratulations to Jeffrey Bluestone, PhD, on being named to The Medicine Maker’s 2026 Power List for Advanced Medicines.
A foundational figure in modern immunotherapy and cell-based medicine, Jeff has spent more than four decades advancing our understanding of T-cell activation, immune tolerance, and regulatory T cells.
Today, his work is helping advance the potential of Treg therapies to transform treatment for patients living with debilitating autoimmune and inflammatory diseases.
We’re proud to celebrate Jeff and his continued leadership in advancing the science and translating it into new possibilities for patients.
Read more about The Medicine Maker’s 2026 Power List: The Power List 2026.”
Other articles featuring Jeffrey Bluestone on OncoDaily.